March 31, 2007 |
A widely prescribed drug for severe constipation is being taken off the market after it was linked to a higher risk of heart attacks and strokes, federal regulators said Friday. Doctors said the voluntary withdrawal of Zelnorm by its manufacturer would leave few options for patients who suffer from a type of irritable bowel syndrome that affects about 12 million Americans, mostly women. "This is really a sort of one-of-a-kind drug," said Dr.
January 14, 2007 |
En Li left China in 1986, convinced that was the best way to become a world-class biologist. The alternative was getting trained at poorly equipped Chinese labs or universities hollowed by the Cultural Revolution. So the graduate of Peking University went to Boston and obtained a doctorate in biology from MIT. He joined the faculty at Harvard Medical School, teaching and doing cutting-edge research in genetics.
January 3, 2007 |
Novartis' Lek unit sued Bristol-Myers Squibb Co. and Watson Pharmaceuticals Inc., seeking royalties on the cholesterol medicine Pravachol. Lek owns two patents for crystalline forms of pravastatin, the key ingredient in Pravachol. Changes in the crystal make the compound more stable and pure, according to the patents issued in May 2004 and July 2006. Lek claims that the Bristol-Myers version of the drug uses pravastatin in the forms covered by the patents. Pravachol, approved by U.S.
December 28, 2006 |
Swiss drug maker Novartis has sued a Baxter International Inc. unit, claiming that it is cutting off supplies of the only drug approved to treat canine Addison's disease, a sometimes fatal glandular disorder in dogs. Novartis Animal Health US Inc., based in Greensboro, N.C., said in a complaint on Friday in Wilmington, Del., that Baxter abruptly ended a 10-year agreement to produce the drug Percorten-V.
December 15, 2006 |
Nestle, the world's biggest food and drink company, will buy the medical nutrition unit of pharmaceutical company Novartis for $2.5 billion, the companies said Thursday. Nestle will acquire such brands as Boost and Resource nutritional supplements, and Optifast dieting products. The deal still needs regulatory approval but is expected to be completed during the second half of 2007, Nestle said.
July 24, 2006 |
A successful cancer-fighting drug may also damage the heart, although a researcher says leukemia patients who need Gleevec should not abandon it. While effectively treating cancer, Gleevec can lead to heart failure in some patients, said Dr. Thomas Force, who teaches medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia.